Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology drug development Drug prices research pharma

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Despite probe, China reimbursing AstraZeneca drug - 19 days ago A win for Apellis, a setback for Astellas - about 1 month ago The biotech news roundup to start your week - about 2 months ago STAT+: Potential competition for RSV prophylactic Beyfortus - 2 months ago Lilly has more positive data on its weekly insulin - 4 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: AstraZeneca says China has detained a senior executive - about 1 month ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 2 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 3 months ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 4 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 4 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more - 8 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 9 months ago STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more - 9 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 11 months ago STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more - 12 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - about 1 year ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - about 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - about 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - about 1 year ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	AstraZeneca falls on reports of Chinese probe - about 1 month ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 2 months ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	News from ESMO: An AstraZeneca win in bladder cancer, and more - 3 months ago STAT+: As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal - 9 months ago STAT+: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal - 9 months ago STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug - 12 months ago STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions - about 1 year ago STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca - about 1 year ago STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial - about 1 year ago
6	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 4 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	AstraZeneca Caps Inhaled Respiratory Portfolio at $35 For Eligible Patients With Asthma, COPD - 9 months ago AstraZeneca to Initiate Trial for Triple-Combination Inhaled Therapy for Chronic Obstructive Pulmonary Disease - 9 months ago
8	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation - 10 months ago
9	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Behind a big-name rare disease biotech, an exec draws from personal experience - 10 months ago Astellas’ science chief on the leap into new technologies - 11 months ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - 11 months ago
10	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 10 months ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - about 1 year ago STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind - over 1 year ago

Journalists covering Astellas